BACKGROUND: Nanoparticles represent promising drug carrier systems. In the case of cytostatics such as doxorubicin, carrier colloid systems as human serum albumin (HSA) nanoparticles, may increase their therapeutic efficiency and decrease their side-effects (toxicity) and any potential multidrug resistance. In the present study, doxorubicin, as a widely used antineoplastic agent, was incorporated into the matrix of human serum albumin and three different particle-sized doxorubicin-loaded HSA nanoparticles were prepared, using a previously described desolvation method. Our objective was to find out if different particle sizes of colloid carriers can allow regarding the given cytostatic agent.
Introduction
In recent years new methods have been developed with nanoparticles as drug delivery systems (nanocarriers) in oncological applications to targeted delivery antineoplastic drugs. The use of colloidal carriers can decrease side-effects in treatment and increase therapeutic efficiency [1] . In cancer therapy doxorubicin is a frequently used antineoplastic agent, but in clinical applications this anti-cancer drug is limited due to its high cardiotoxicity [2, 3] . A promising solution to decrease cardiotoxicity could be binding doxorubicin to a drug delivery nanoparticle system [4] .
Nanoparticles show a high drug loading efficiency with minor drug leakage, high storage stability, and may overcome cancer cell multidrug resistance [5, 6] . Earlier, doxorubicin was bound to colloidal carriers made from several agents such as poly(butyl cyanoacrylate) (PBCA) [7, 8] , poly(isohexyl cyanoacrylate) (PIHCA) [9] , poly(lactic-co-glycolic acid) (PLGA) [10] , and gelatin [11, 12] . Original the enhanced permeation and retention effect (EPR effect, [13] ) that results from the properly selected particle-size distribution, and secondly, elimination of the multidrug resistance in more cancer cell lines [14] . Several methods have been described for bounding drugs to nanoparticulate systems, such as surface attachment of drugs to nanoparticles or polymers [6, 15] , adsorption to the preformed carrier system, and incorporation into the particle matrix during colloid preparation [4] . While simple adsorption to preformed carrier nanoparticles could lead to the early desorption of targeting ligand, incorporation protects drug-loaded particles from early drug loss, inactivation, or degradation during storage and after administration [4] .
In the present study, doxorubicin was incorporated into the matrix of human serum albumin, and three different particle-sized fractions of doxorubicin-loaded HSA nanoparticles were prepared using a previously described desolvation method [16, 17] . HSA nanoparticles offer several specific advantages [16] : these colloid compounds are biodegradable and well-tolerated, preparation is easy and reproducible [17] , and it is possible to bind targeting ligands to particles by covalent bonding, due to the presence of functional groups [18] [19] [20] [21] .
The attained nanoparticles were labelled with technetium (Tc-99m) and investigated for their physicochemical (doxorubicin-conjugating) radiochemical purity. Particle sizes and their stabilities and fluctuations were measured by dynamic light scattering, and examinations were reinforced by TEM images.
Different biodistributions of different sized radiocolloids were investigated in healthy Wistar rats. A previously designed protocol was applied to find out correlations with earlier biodistribution studies of comparable particle-sized nanoparticles [22] [23] [24] [25] [26] . Our further aim was to verify the lack of any incidental, too high particle-size fluctuations and degradation after intravenous injection. 
Material and methods

Chemicals
Determination of non-adsorbed doxorubicin proportion
After centrifugation (16, RP-18 reverse phase column (Merck, Germany) was used for the assay, and separation was achieved using an isocratic mixture of water and acetonitrile (7:3) containing 0.1% trifluoroacetic acid [28] at a flow rate of 0.8 ml/min. Doxorubicin was quantified by UV (250 nm), and the retention time was about 12 min [4] . Non-adsorbed doxorubicin quota was followed up 1 and 24 hours and 7 days after preparation. Samples were stored at RT in a dark place.
Characterization of particle size and colloid stability
Particle size and polydispersity of attained colloids were measured by dynamic light scattering using a Dynapro instrument (Proteinsolutions Inc., VA, USA) as described earlier [23] . Samples were diluted 1:10 with saline and were measured at room temperature. Colloidal stability of nanoparticles was followed up 1, 2, 8, and 24 hours and 2, 4, and 7 days after preparation. Samples were stored at RT in a dark place.
Transmission electron-microscopy examinations
Although particle fraction-ranges of the examined samples were near to the upper threshold of the measuring range for laser a scattering instrument (6 microns), TEM examinations were carried out to verify that the particles were in the earlier determined ranges.
Doxorubicin-loaded HSA nanoparticle solutions were prepared according to the single-droplet negative staining technique [29] using carbon coated formvar copper grids and ammonium molybdate as a contrasting solution, and they were examined with a transmission electron-microscope (TEM) at various magnifications (JEOL, Japan TcO 4 -(aqueous pertechnetate solution) was added to the solvent. Labelling was performed in 60 min incubation at RT [28] . Radiochemical purity was examined by means of thin layer chromatography, using silica gel as the coating substance on a glass-fibre sheet (ITLC-SG) [30] . Plates were developed in methyl ethyl ketone. We applied a Raytest MiniGita device (Mini Gamma Isotope Thin Layer Analyzer) in Radiopharmacy Ltd. to determine the distribution of radioactivity in the developed ITLC-SG plates. We examined labelling efficiency 1, 6, and 24 h after labelling. Radiochemical samples were stored at RT in a dark place.
In vivo examinations, animal experiments
The aim of in vivo examinations was to observe particle-size changes or degradation after intravenous injection and to find out possible correlations with earlier presented biodistribution results of HSA colloids among the same size-ranges. These HSA products were earlier described in studies concerned with lymphoscintigraphy [23] , lung scintigraphy [22] , and other particle size-dependent biodistribution tests [25, 26] . keV gamma photon of 99m Tc. All the images were acquired with 60 second time-prerequisites using a 1024 × 1024 × 16 matrix size. Critical organs, e.g. heart, liver, spleen, shoulder (representing the bone marrow uptake), and urinary bladder, were drawn around and organ uptakes were estimated by quantitative ROI analysis.
All the animal experiments reported here were carried out in strict compliance with the relevant national laws of Hungary.
This study was approved by the Institutional Ethical Board.
Results
Non-conjugated doxorubicin concentration
Quantification of doxorubicin in the supernatant samples showed that at 1.0 mg/ml doxorubicin concentration more than 95% of the drug was adsorbed to nanoparticles. Doxorubicin loading efficiency was examined 6, 24, and 48 h after biological application of labelled nanoparticles and each quantification showed that more than 95% of the doxorubicin remained bound to the HSA.
Particle size measurements and colloid stability
For the radiolabelling experiments three samples were manufactured with different mean diameters (about 180, 430, and 1800 nm) and particle-size distributions at different initial pH settings in due course of preparation. Fractions of nanoparticles are illustrated in a common particle-size distribution histogram (Figure 1) .
Representative values of nanoparticle fractions are summarized in Table 1 . Relatively high (35...45%) polydispersity values belong to mean diameters (MD) 180, 430, and 1800 nm.
Fluctuations of particle-sizes were followed up for 1 week and the average diameter, polydispersity, and fraction-range values were measured at different times. Results are summarized in Table 2 and illustrated in Figure 2 Original and 1.2% average particle-size growth, while the 1800 nm MD nanoparticles had 1.9% average diameter decrease during the follow-up. Thus doxorubicin-loaded nanoparticles showed a high degree of particle-size stability.
At different times, mean particle-diameters showed fluctuations with an ± SD = 3.5…4.7%, but average particle size changes were insignificant during the 1 st week (Table 2) .
TEM images of colloids
The TEM examination revealed the presence of mostly spherical-shaped particles ( Figure 3 ). Each sample showed broad size-distribution, but each observed size of particles was in the previously determined particle-fraction ranges. Besides, we could not see any particles larger than 6 microns in the largest product ( 99m Tc-Doxo-HSA-Coll1800). It was important because the upper threshold of size-measuring in the applied laser scattering method was 6 microns. Thus, light scattering measurements were reinforced by TEM images.
Labelling efficiency, radiochemical purity, and stability
Efficiency of Tc-99m binding was examined 1, 6, and 24 h after labelling. Radiochemical samples were stored at RT in a dark place. Measurements verified that 1 hour after labelling each colloid had at least 95% radiochemical efficiency and 6 and 24 h after labelling the products kept radiochemical stability. Measured labelling efficiencies even increased to 98…99% (Figure 4 ).
In vivo examinations
All the injected animals survived the experiments and no clinical side-effects (screaming, salivation, tremor, dyspnoe, diarrhoea, restlessness, or state of coma) were recorded in the rats. There was no sign of radioactivity in thyroid, salivary gland, or gastric mucosa at any time, indicating a high radioactive yield and stable in vivo labelling of all three agents.
The applied radiolabelled nanoparticles disappeared from the blood-stream relatively quickly. In the first 5 minutes post-ap- Tc-Doxo-HSA-Coll1800.
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Original plication, no large vessels were visualized. The two smaller particles were quickly taken up by the RES organs (liver, spleen, bone marrow) and the accumulated radioactivity immediately started to wash-out through the urinary tract (kidneys, urinary bladder, urine). However, almost 80% of the applied greatest radiolabelled agent localized in the lungs, even on the first scans ( Figure 5 ).
Only minor differences were recognized between the colloid particles No. 1 and 2 (average diameter 180 nm and 430 nm),
respectively. Both radiocolloids were excreted in the same amount (nearly 50% in 22 hours post application) through the urinary tract of the animals.
The greater doxorubicin-loaded colloid ( 99m Tc-Doxo-HSA-Coll 1800), however, markedly differed from the two smaller ones. The major proportion of radioactivity (78.6%) appeared in the lungs, much less but increasing and visible in the liver, and no appearance was documented in the scans in the spleen and skeleton (Table 3, Figure 6 ). The greater radiolabelled compounds located in the lungs disaggregated later, and the smaller particles relocated mainly in the liver (Table 3A , 3B, Figure 7 ). This is the explanation of the observation that the measured radioactivity Tc-Doxo-HSA-Coll1800. Biodistributions showed close correlation to earlier pharmacokinetic studies [22] [23] [24] [25] [26] However, 6 hours and almost 1 day after IV application, colloid agents showed the proper distribution according to their particle size and less than 50% of injected activity excreted through the urinary tract.
Discussion
The present study demonstrates the preparation and investigation of doxorubicin-loaded HSA nanoparticles in different particle-sizes. Three samples, different by means of particle-size distribution and fraction-range, were considered for the experiments. Non-adsorbed doxorubicin quota was checked and followed-up respectively, until 7 days after preparation, and verified that more than 95% of doxorubicin proportion was permanently adsorbed to human serum albumin. The prepared doxorubicin-loaded particles were radiolabelled by 99m
Tc with high-degree and durable labelling efficiency as the in vitro radiochemical stability measurements demonstrates. Another aspect is the size stability: particle size was observed for 1 week.
Each product showed a high degree of colloid size-stability: diameters and polydispersities of particle fractions fluctuated within a relatively narrow range and changes were not unidirectional, nor trend-like.
The different biological behaviours of the different-sized colloids were examined by scintigraphic imaging studies in healthy male Wistar rats. Ventrodorsal and left-lateral images were taken with a digital SPECT gamma camera at different times till 22 h post injection and organ uptakes were estimated by quantitative ROI analysis.
The in vivo biodistribution data of doxorubicin-loaded radiocolloids had a very close correlation to earlier described results [22] [23] [24] [25] [26] .
Images and calculated injected dose percentage values em- Original phasized that directly post-injection, the greatest particle-sized compounds were located especially in the lungs and they slowly disaggregated. The smaller particle fractions were relocated mainly in the liver and they also had slow eliminationOur investigations verified that application of different particle sized doxorubicin-loaded HSA nanoparticles make drug carrier systems possible to apply different drug targeting in potential clinical use.
